Neurodegenerative diseases, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS), are characterized by progressive neuronal damage and functional decline, significantly affecting the quality of life of those impacted. Early diagnosis is crucial for better disease management and improving therapeutic outcomes, yet the clinical diagnosis of these conditions is often made at advanced stages when irreversible neuronal damage has already occurred. Currently, most neurodegenerative diseases are diagnosed through clinical evaluation, neuroimaging, and sometimes post-mortem examination, but these methods lack the sensitivity and specificity needed for early detection. As a result, there is an urgent need for the development of novel molecular biomarkers that can detect these diseases at an earlier stage, before the onset of significant clinical symptoms. Molecular biomarkers, such as proteins, metabolites, and genetic markers, hold great potential to provide earlier, more accurate diagnoses and to track disease progression. Advances in genomics, proteomics, and metabolomics have opened up new avenues for identifying these biomarkers, which could revolutionize the way we diagnose and monitor neurodegenerative disease.
HTML PDF
Share this article
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
